Slides on The Promise of Individualized HIV Prevention: Future Formulations and Dosing Intervals for Long-Acting PrEP

Consider expert perspectives on the different antiretroviral drug formulations and dosing strategies in various stages of clinical development for long-acting HIV PrEP—advances that collectively offer the potential for highly individualized approaches to HIV biomedical prevention.
Nicholas Chamberlain, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 473 KB
Released: October 15, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Gilead Sciences, Inc.

Related Content

Breve vlog de la Dra. Alicia Piñeirúa Menéndez sobre la optimización del TAR en un paciente con VIH y tuberculosis activa en México de Clinical Care Options (CCO)

person default Alicia Piñeirúa Menéndez, MD, MPH Released: May 20, 2022

Leticia M. Pérez Saleme, MD Released: May 19, 2022

Preguntas respondidas por expertas de Clinical Care Options (CCO) sobre las mejores prácticas para cambiar el TAR en pacientes suprimidos en México.

person default Alicia Piñeirúa Menéndez, MD, MPH Leticia M. Pérez Saleme, MD Released: May 17, 2022

Expert HIV faculty analyze new data from CROI 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN Jasjit Gill, BSPharm, PharmD
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: May 10, 2022 Expired: May 9, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings